Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease

adenocarcinoma

Age

60 years

Gender

female

Ethnicity

Caucasian

Storage Conditions

liquid nitrogen vapor phase

Karyotype

The stemline chromosome number is hypotetraploid, with the 2S component occurring at 4.4%. Marker chromosomes 1p, t(1q;11q); 11q+; t(13;?); 16q+; t(12q; 18q); M10; t(2q;13q); i(15); and ?t(xp;21q) occurred in all S metaphases, and t(1p;?); t(1p;14q); t(16;?), and t(14;21) occurred in some. In addition, 4 to 9 small markers of unidentifiable origin occurred frequently. Chromosome No. 7 was generally hexasomic, X chromosomes were disomic, and normal No. 15 was absent. No Y chromosome was detected in the QM stained preparation.

Clinical Data

60 years

Caucasian

female

Antigen Expression

Antigen expression: Blood Type O; Rh+; HLA Aw24, Aw32, B27, Bw41

Tumorigenic

Yes

Effects

Yes, in immunotolerant rats

Comments

Mycoplasma contamination was detected and eliminated in 1971.

Complete Growth Medium

The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the cells subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with the Office of Technology Development, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Contact email: otd@mskcc.org